Is it rational to continue anti-neoplastics with minimal toxicity even after progression in patients with no other options? Possibly yes


Sezer A., Sumbul A. T., Abali H.

Asian Pacific Journal of Cancer Prevention, vol.15, no.2, pp.1061-1062, 2014 (SCI-Expanded, Scopus) identifier identifier identifier